Medical News / Newscasting from ASH 2022: Crizanlizumab Reduces Priapic Events in Men with Sickle Cell Disease

Crizanlizumab was associated with a halved likelihood of priapic events among treated patients with sickle cell disease-related priapism, according to findings from a phase 2 trial. In new data from the SPARTAN trial presented at the American Society of Hematology (ASH) 2022 Annual Meeting in New Orleans last week, a team of US investigators observed that the monoclonal antibody was associated with a reduction in priapic episodes over a half-year of treatment. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

In data presented as a late-breaking abstract during Digestive Disease Week (DDW) 2023 in Chicago, a ... read more
Direct endoscopic necrosectomy at index session, as opposed to the step-up approach, for patients with infected ... read more
Gut dysbiosis is often linked to persistent multi-system symptoms after SARS-CoV-2 infections or post-acute COVID-19 syndrome. In ... read more
The explosion of artificial intelligence has permeated through basically all walks of life, including medicine. In an ... read more